364 related articles for article (PubMed ID: 9816195)
21. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
Rosenthal NS; Hank JA; Kohler PC; Minkoff DZ; Moore KH; Bechhofer R; Hong R; Storer B; Sondel PM
J Biol Response Mod; 1988 Apr; 7(2):123-39. PubMed ID: 3258904
[TBL] [Abstract][Full Text] [Related]
22. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
23. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
24. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
26. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
28. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
29. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
30. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
Sondel PM; Kohler PC; Hank JA; Moore KH; Rosenthal NS; Sosman JA; Bechhofer R; Storer B
Cancer Res; 1988 May; 48(9):2561-7. PubMed ID: 3258545
[TBL] [Abstract][Full Text] [Related]
31. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
[TBL] [Abstract][Full Text] [Related]
32. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
Lotze MT; Matory YL; Ettinghausen SE; Rayner AA; Sharrow SO; Seipp CA; Custer MC; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2865-75. PubMed ID: 2993418
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.
Legha SS; Gianan MA; Plager C; Eton OE; Papadopoulous NE
Cancer; 1996 Jan; 77(1):89-96. PubMed ID: 8630945
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
[TBL] [Abstract][Full Text] [Related]
37. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
[TBL] [Abstract][Full Text] [Related]
38. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
40. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury.
Aronson FR; Libby P; Brandon EP; Janicka MW; Mier JW
J Immunol; 1988 Jul; 141(1):158-63. PubMed ID: 3259966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
